Soleno Therapeutics Inc. (NASDAQ:SLNO) shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback